In a filing, Neurocrine Biosciences, Inc revealed its Chief Regulatory Officer Delaet Ingrid unloaded Company’s shares for reported $61695.0 on Jul 10 ’25. In the deal valued at $135.00 per share,457 shares were sold. As a result of this transaction, Delaet Ingrid now holds 4,730 shares worth roughly $0.61 million.
Then, Onyia Jude sold 59,819 shares, generating $7,803,688 in total proceeds. Upon selling the shares at $130.46, the Chief Scientific Officer now owns 18,289 shares.
Before that, INGRID DELAET bought 457 shares. Neurocrine Biosciences, Inc shares valued at $61,014 were divested by the Officer at a price of $133.51 per share.
Truist initiated its Neurocrine Biosciences, Inc [NBIX] rating to a Buy in a research note published on July 21, 2025; the price target was $163. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in early July with a ‘”a Buy”‘ rating. Needham also remained covering NBIX and has increased its forecast on April 15, 2025 with a “Buy” recommendation from previously “Hold” rating. RBC Capital Mkts revised its rating on April 14, 2025. It rated NBIX as “an Outperform” which previously was an “a Sector perform”.
Price Performance Review of NBIX
On Monday, Neurocrine Biosciences, Inc [NASDAQ:NBIX] saw its stock fall -0.67% to $128.04. Over the last five days, the stock has lost -4.24%. Neurocrine Biosciences, Inc shares have fallen nearly -9.56% since the year began. Nevertheless, the stocks have fallen -6.20% over the past one year.
How much short interest is there in Neurocrine Biosciences, Inc?
A steep rise in short interest was recorded in Neurocrine Biosciences, Inc stocks on 2025-07-15, dropping by -0.26 million shares to a total of 3.23 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 3.5 million shares. There was a decline of -8.07%, which implies that there is a negative sentiment for the stock.
